TCGA-ZF-A9R9-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 28.38370565
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.480
- COAGULATION+0.410
- MYOGENESIS+0.400
- HEDGEHOG_SIGNALING+0.390
- KRAS_SIGNALING_DN+0.360
- BILE_ACID_METABOLISM+0.340
- PANCREAS_BETA_CELLS+0.340
- KRAS_SIGNALING_UP+0.240
- XENOBIOTIC_METABOLISM+0.170
Top 10 suppressed
- MYC_TARGETS_V1-0.700
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V2-0.600
- OXIDATIVE_PHOSPHORYLATION-0.570
- PROTEIN_SECRETION-0.570
- UNFOLDED_PROTEIN_RESPONSE-0.550
- MITOTIC_SPINDLE-0.510
- MTORC1_SIGNALING-0.510
- PI3K_AKT_MTOR_SIGNALING-0.480
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UY-A8OD-01A-11R-A36F-07 | — | — | 0.948 |
| 2 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.943 |
| 3 | SRR12202400 | — | — | 0.934 |
| 4 | MNG204 | — | — | 0.930 |
| 5 | SRR1330061 | GTEX | — | 0.924 |
| 6 | MNG768 | — | — | 0.923 |
| 7 | SRR1434138 | GTEX | — | 0.918 |
| 8 | SRR1317853 | GTEX | — | 0.918 |
| 9 | SRR1378155 | GTEX | — | 0.917 |
| 10 | SRR1472079 | GTEX | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |